UY35801A - Compuesto heterocíclico - Google Patents
Compuesto heterocíclicoInfo
- Publication number
- UY35801A UY35801A UY0001035801A UY35801A UY35801A UY 35801 A UY35801 A UY 35801A UY 0001035801 A UY0001035801 A UY 0001035801A UY 35801 A UY35801 A UY 35801A UY 35801 A UY35801 A UY 35801A
- Authority
- UY
- Uruguay
- Prior art keywords
- compound
- salt
- heterocyclic compound
- medicament
- sstr5
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Se proporciona un compuesto que tiene una acción antagonista del SSTR5 y el uso del compuesto como medicamento. De forma específica, se proporciona un compuesto representado por la fórmula que aparece a continuación: en donde cada símbolo es como s e lo define en la presente, o una sal de él, un medicamento que comprende el compuesto o una sal de él, y el uso del compuesto o una sal de él como agente para la profilaxis o el tratamiento de la diabetes mellitus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013224093 | 2013-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35801A true UY35801A (es) | 2015-06-30 |
Family
ID=51932560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035801A UY35801A (es) | 2013-10-29 | 2014-10-28 | Compuesto heterocíclico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9120777B2 (es) |
| EP (1) | EP3063139B1 (es) |
| JP (1) | JP6450755B2 (es) |
| AR (2) | AR098215A1 (es) |
| CY (1) | CY1121279T1 (es) |
| DK (1) | DK3063139T3 (es) |
| ES (1) | ES2710657T3 (es) |
| HR (1) | HRP20190133T1 (es) |
| HU (1) | HUE041792T2 (es) |
| LT (1) | LT3063139T (es) |
| PL (1) | PL3063139T3 (es) |
| PT (1) | PT3063139T (es) |
| RS (1) | RS58321B1 (es) |
| SI (1) | SI3063139T1 (es) |
| SM (1) | SMT201900101T1 (es) |
| TR (1) | TR201901986T4 (es) |
| TW (1) | TWI668214B (es) |
| UY (1) | UY35801A (es) |
| WO (1) | WO2015064083A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6121339B2 (ja) * | 2012-02-13 | 2017-04-26 | 武田薬品工業株式会社 | 芳香環化合物 |
| US9605000B2 (en) * | 2013-03-14 | 2017-03-28 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists |
| JO3442B1 (ar) | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) |
| EP4077310B1 (en) * | 2019-12-19 | 2024-05-01 | Université de Strasbourg | Sigma-1 receptor ligands and uses thereof |
| CN116354961A (zh) * | 2021-12-27 | 2023-06-30 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其药物组合物及用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356906A (en) | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
| ATE420862T1 (de) | 2000-06-12 | 2009-01-15 | Eisai R&D Man Co Ltd | 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| MXPA05009771A (es) | 2003-03-14 | 2005-10-26 | Ono Pharmaceutical Co | Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo. |
| WO2005047249A1 (en) | 2003-11-10 | 2005-05-26 | Schering Aktiengesellschaft | Benzylether amine compounds useful as ccr-5 antagonists |
| US7754744B2 (en) | 2006-08-15 | 2010-07-13 | Hoffmann-La Roche Inc. | Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists |
| US7862825B2 (en) | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
| US7799806B2 (en) | 2007-04-04 | 2010-09-21 | Hoffmann-La Roche Inc. | Substituted n-benzyl piperidines as somatostatin receptor modulators |
| US20080306116A1 (en) | 2007-06-08 | 2008-12-11 | Christ Andreas D | Aryloxazole, aryloxadiazole and benzimidazole derivatives |
| TW200918062A (en) | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| US20120041012A1 (en) | 2009-05-07 | 2012-02-16 | Aster Susan D | Substituted spirocyclic amines useful as antidiabetic compounds |
| US8742110B2 (en) | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| US9000175B2 (en) | 2010-11-26 | 2015-04-07 | Lupin Limited | Bicyclic GPR119 modulators |
| US9605000B2 (en) | 2013-03-14 | 2017-03-28 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists |
-
2014
- 2014-10-28 EP EP14800152.2A patent/EP3063139B1/en active Active
- 2014-10-28 WO PCT/JP2014/005438 patent/WO2015064083A1/en active Application Filing
- 2014-10-28 RS RS20190190A patent/RS58321B1/sr unknown
- 2014-10-28 AR ARP140104043A patent/AR098215A1/es active IP Right Grant
- 2014-10-28 UY UY0001035801A patent/UY35801A/es not_active Application Discontinuation
- 2014-10-28 DK DK14800152.2T patent/DK3063139T3/en active
- 2014-10-28 TR TR2019/01986T patent/TR201901986T4/tr unknown
- 2014-10-28 PL PL14800152T patent/PL3063139T3/pl unknown
- 2014-10-28 JP JP2016526960A patent/JP6450755B2/ja active Active
- 2014-10-28 HU HUE14800152A patent/HUE041792T2/hu unknown
- 2014-10-28 ES ES14800152T patent/ES2710657T3/es active Active
- 2014-10-28 US US14/525,593 patent/US9120777B2/en active Active
- 2014-10-28 SM SM20190101T patent/SMT201900101T1/it unknown
- 2014-10-28 LT LTEP14800152.2T patent/LT3063139T/lt unknown
- 2014-10-28 SI SI201431055T patent/SI3063139T1/sl unknown
- 2014-10-28 PT PT14800152T patent/PT3063139T/pt unknown
- 2014-10-28 TW TW103137143A patent/TWI668214B/zh active
-
2019
- 2019-01-21 HR HRP20190133TT patent/HRP20190133T1/hr unknown
- 2019-02-14 CY CY20191100202T patent/CY1121279T1/el unknown
-
2022
- 2022-12-29 AR ARP220103645A patent/AR128158A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI668214B (zh) | 2019-08-11 |
| SI3063139T1 (sl) | 2019-03-29 |
| US9120777B2 (en) | 2015-09-01 |
| US20150119412A1 (en) | 2015-04-30 |
| DK3063139T3 (en) | 2019-03-11 |
| AR128158A2 (es) | 2024-03-27 |
| HRP20190133T1 (hr) | 2019-03-22 |
| WO2015064083A1 (en) | 2015-05-07 |
| CY1121279T1 (el) | 2020-05-29 |
| AR098215A1 (es) | 2016-05-18 |
| JP2016535040A (ja) | 2016-11-10 |
| SMT201900101T1 (it) | 2019-02-28 |
| PT3063139T (pt) | 2019-02-22 |
| TR201901986T4 (tr) | 2019-03-21 |
| EP3063139B1 (en) | 2018-11-21 |
| LT3063139T (lt) | 2019-02-25 |
| EP3063139A1 (en) | 2016-09-07 |
| RS58321B1 (sr) | 2019-03-29 |
| TW201542539A (zh) | 2015-11-16 |
| ES2710657T3 (es) | 2019-04-26 |
| HUE041792T2 (hu) | 2019-05-28 |
| PL3063139T3 (pl) | 2019-05-31 |
| JP6450755B2 (ja) | 2019-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35774A (es) | Compuesto heterocíclico | |
| DOP2016000206A (es) | Compuesto heterocíclico fusionado | |
| UY35995A (es) | Compuesto heterocíclico | |
| AR128158A2 (es) | Compuesto heterocíclico | |
| CL2017003404A1 (es) | Compuestos antibacterianos | |
| UY35589A (es) | Compuesto peptídico | |
| CR20150205S (es) | Almohada de viaje | |
| DK3174868T3 (da) | Forbindelser, der er aktive mod bromodomæner | |
| DOP2015000140A (es) | Compuesto heterocíclico | |
| LT2984166T (lt) | Kompozicijos, skirtos mpsi gydymui | |
| UY35322A (es) | Compuestos derivados y conjugados de tubulisina, métodos para obtenerlos y uso | |
| CR20140537A (es) | Compuesto heterocíclico nitrogenado | |
| MX2013006113A (es) | Compuestos biciclico. | |
| CO2017003699A2 (es) | Compuesto heterocíclico | |
| CL2016000190A1 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca. | |
| CU20160003A7 (es) | Pirazololpiridinaminas sustituidas | |
| CL2016001210A1 (es) | Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis. | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| MX2015016628A (es) | Metodo para tratar infeccion intracelular. | |
| CL2015002612A1 (es) | Oligonucletotidos antisentido para el tratamiento de células madre del cáncer. | |
| UY35650A (es) | Compuesto heterocíclico | |
| EA201691036A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| ES1102512Y (es) | Dispositivo para la aplicacion de acciones terapeuticas sobre el cuerpo. | |
| CL2015003736A1 (es) | Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol | |
| UY34752A (es) | Agentes para el control de la chinche del eucalipto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211215 |